Healio (5/27, Gramigna) reports, “Esketamine nasal spray appeared to rapidly reduce depressive symptoms among severely ill patients with major depressive disorder [MDD] who had active suicidal ideation with intent,” investigators concluded in the 226-patient, “double-blind, randomized phase 3 ASPIRE I study,” the findings of which were published online in the Journal of Clinical Psychiatry (SOURCE: APA Headlines)